UBS Group
LUCD icon

UBS Group’s Lucid Diagnostics LUCD Stock Holding History

UBS Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$512K Buy
445,479
+135,985
+44% +$173K ﹤0.01% 6069
2025
Q4 		$337K Buy
309,494
+164,250
+113% +$184K ﹤0.01% 6289
2025
Q3 		$147K Buy
145,244
+78,459
+117% +$85.7K ﹤0.01% 6865
2025
Q2 		$76.8K Buy
66,785
+60,935
+1,042% +$78.7K ﹤0.01% 7445
2025
Q1 		$8.72K Buy
+5,850
New +$7.02K ﹤0.01% 8733
2024
Q4 		– Sell
-2
Closed -$2 – 10210
2024
Q3 		$2 Buy
+2
New +$2 ﹤0.01% 9416
2024
Q1 		– Sell
-5,708
Closed -$8.05K – 9737
2023
Q4 		$8.05K Buy
5,708
+192
+3% +$253 ﹤0.01% 7585
2023
Q3 		$6.45K Buy
+5,516
New +$8K ﹤0.01% 7300
2023
Q2 		– Sell
-2,558
Closed -$3.58K – 9330
2023
Q1 		$3.58K Sell
2,558
-1,007
-28% -$1.39K ﹤0.01% 8300
2022
Q4 		$4.85K Sell
3,565
-1,396
-28% -$2.51K ﹤0.01% 9269
2022
Q3 		$8K Buy
4,961
+374
+8% +$931 ﹤0.01% 8728
2022
Q2 		$10K Buy
4,587
+3,103
+209% +$6.89K ﹤0.01% 7974
2022
Q1 		$5K Sell
1,484
-404
-21% -$1.48K ﹤0.01% 9139
2021
Q4 		$10K Buy
+1,888
New +$15.3K ﹤0.01% 8786

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

UBS Group's LUCD Position: Q1 2026 in Review

UBS Group increased its Lucid Diagnostics (LUCD) stake by 44% in Q1 2026, buying an estimated $173K and bringing the position to 445,479 shares worth $512K. The position accounts for ﹤0.01% of the portfolio, ranked #6069.

UBS Group first reported a position in LUCD in Q4 2021 and has held it in 14 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • UBS Group held 445,479 shares of Lucid Diagnostics worth $512K as of Q1 2026.
  • UBS Group bought 135,985 Lucid Diagnostics shares in Q1 2026, an estimated $173K.
  • Lucid Diagnostics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6069 holding.
  • UBS Group first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 14 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.